The biopharmaceutical industry’s funding trends, product pipeline, and pace of R&D spending indicate demand is set to improve this year, say William Blair analysts.
The Hangzhou facility achieved licensure just two months after qualification and will hold a total capacity of 172,000 liters upon completion, according to the announcement.
The engineering campaign validated the company’s expanded mammalian manufacturing suites for late-stage and commercial biologics production at its San Diego site.
